MCL Clinical Trials
1230 trials from ClinicalTrials.gov. Recruiting trials shown first.
Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer
COMPLETEDNCT00546377·PHASE1 / PHASE2·Memorial Sloan Kettering Cancer Center·50 enrolled
filgrastimpegfilgrastimrituximabsargramostimcyclophosphamide+8 more
Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
COMPLETEDNCT00863369·PHASE1 / PHASE2·City of Hope Medical Center·33 enrolled
rituximabbortezomibgemcitabine hydrochloridequestionnaire administration
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
COMPLETEDNCT00114738·PHASE2·National Cancer Institute (NCI)·53 enrolled
Rituximab (R)EPOCHBortezomib (B)BortezomibBortezomib or observation
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
COMPLETEDNCT00611351·PHASE2·University of Nebraska·5 enrolled
anti-thymocyte globulinbusulfancyclophosphamidemycophenolate mofetiltacrolimus+9 more
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
COMPLETEDNCT00186628·PHASE2·Stanford University·36 enrolled
Total lymphoid irradiationRituximabAnti-thymoglobulin, rabbit (ATG, rabbit ATG)CyclosporineMycophenylate mofetil+6 more
Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer
TERMINATEDNCT00295880·PHASE1 / PHASE2·Masonic Cancer Center, University of Minnesota·12 enrolled
umbilical cord blood transplantation
BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma
COMPLETEDNCT00126646·PHASE1·MedImmune LLC·24 enrolled
BL22 immunotoxinantibody-drug conjugate therapyimmunotoxin therapy
Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell Lymphoma
COMPLETEDNCT00234026·PHASE2·Swiss Cancer Institute
gemcitabine hydrochloride
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
COMPLETEDNCT00245037·PHASE1 / PHASE2·OHSU Knight Cancer Institute·147 enrolled
therapeutic allogeneic lymphocytesbusulfancyclosporinefludarabine phosphatemycophenolate mofetil+5 more
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma
UNKNOWNNCT00397800·PHASE1 / PHASE2·Technical University of Munich·12 enrolled
rituximabcyclophosphamidefludarabine phosphateyttrium Y 90 ibritumomab tiuxetan
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
COMPLETEDNCT01000753·Children's Oncology Group·174 enrolled
Cytology Specimen Collection Procedure
CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
COMPLETEDNCT00109967·PHASE2·National Cancer Institute (NCI)·71 enrolled
rituximabtemsirolimus
Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma
COMPLETEDNCT00581776·PHASE2·University of Wisconsin, Madison·30 enrolled
BortezomibRituximabCyclophosphamideDoxorubicinVincristine+1 more
Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases
COMPLETEDNCT00317785·PHASE2·Fred Hutchinson Cancer Center·50 enrolled
cyclophosphamidecyclosporinemethotrexatemycophenolate mofetilsirolimus+6 more
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
TERMINATEDNCT00818961·PHASE2·Northside Hospital, Inc.·36 enrolled
alemtuzumabgraft-versus-tumor induction therapyrituximabbusulfancyclophosphamide+4 more
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
COMPLETEDNCT00666211·PHASE3·Vanderbilt-Ingram Cancer Center·98 enrolled
educational interventionTitrated pain managementquestionnaire administration
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia
UNKNOWNNCT00295997·NA·University of California, San Francisco·35 enrolled
anti-thymocyte globulinfilgrastimgraft-versus-tumor induction therapytherapeutic allogeneic lymphocytesbusulfan+8 more
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
COMPLETEDNCT00117598·PHASE3·Pfizer·169 enrolled
Temsirolimus (CCI-779)Temsirolimus (CCI-779)Investigator's choice
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
TERMINATEDNCT00103272·PHASE1·National Cancer Institute (NCI)·74 enrolled
tanespimycinbortezomib
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
COMPLETEDNCT00238433·PHASE2·OHSU Knight Cancer Institute·37 enrolled
filgrastimbusulfanmelphalanthiotepabone marrow ablation with stem cell support+1 more
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
COMPLETEDNCT00118352·PHASE2·Fred Hutchinson Cancer Center·12 enrolled
alemtuzumabtotal-body irradiationfludarabine phosphatecyclosporinemycophenolate mofetil+4 more
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
COMPLETEDNCT00110045·PHASE2·European Organisation for Research and Treatment of Cancer - EORTC·171 enrolled
caspofungin acetate
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
COMPLETEDNCT00104923·PHASE1·California Cancer Consortium·29 enrolled
fenretinide
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
COMPLETEDNCT00119730·PHASE2·Dana-Farber Cancer Institute·30 enrolled
FludarabineMitoxantroneRituximabZevalin
Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant
COMPLETEDNCT00445952·European Organisation for Research and Treatment of Cancer - EORTC·304 enrolled
clinical observationmanagement of therapy complications
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
COMPLETEDNCT00117988·PHASE2·National Cancer Institute (NCI)·22 enrolled
tanespimycin
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
TERMINATEDNCT00176475·PHASE1·University of Medicine and Dentistry of New Jersey·2 enrolled
rituximabtherapeutic allogeneic lymphocytes
Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202
COMPLETEDNCT00896662·Vanderbilt-Ingram Cancer Center·9 enrolled
immunologic techniquelaboratory biomarker analysispharmacological study
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma
COMPLETEDNCT00278161·PHASE2·Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·94 enrolled
PegfilgrastimRituximabCyclophosphamide
Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma
UNKNOWNNCT00261612·PHASE2·Medical University of Vienna·16 enrolled
bortezomibrituximabdexamethasonetreatment protocol